Forma Therapeutics Holdings

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk

Bagsværd, Denmark, 14 October 2022 – Novo Nordisk today announced that the acquisition of Forma Therapeutics Holdings, Inc. (Forma), announced on 1 September 2022, has been completed.

Novo Nordisk announces the completion of the Forma Therapeutics acquisition

Akero Therapeutics Inc

Amgen

Biogen

bluebird bio

Chemocentryx

iShares Nasdaq Biotechnology ETF

Karuna Therapeutics Inc

Pfizer

Rhythm Pharmaceuticals

SPDR S&P Biotech ETF

Biotechs are relatively better positioned in this fourth quarter compared to the broader market. Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach.

Biotech Stocks Well-Positioned For Fourth Quarter

HANOVER, MD and WATERTOWN, Mass.--(BUSINESS WIRE)--Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease

Sickle Cell Disease Association of America & Partners Launch New PSA to Boost Awareness and Understanding of the Disease

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forma Therapeutics, Holdings Inc. (NasdaqGM: FMTX) to Novo Nordisk A/S (NYSE: NVO). Under the terms of the proposed transaction, shareholders of Forma will receive $20 in cash for each share of Forma that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa

FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX

Gemini Therapeutics

Signify Health

Turquoise Hill Resources

NEW YORK , Sept. 26, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Gemini Therapeutics, Inc. (NASDAQ: GMTX) 's  merger with Disc Medicine, Inc. Pre-merger Gemini shareholders are expected to own approximately 28% of the combined company.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY

CyberOptics

Infrastructure & Energy Alternatives

NEW YORK , Sept. 19, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Infrastructure & Energy Alternatives, Inc. (NASDAQ: IEA) 's  sale to MasTec for $10.50 per share in cash and 0.0483 of a MasTec share for each IEA share.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IEA, CYBE, FMTX, TRQ

Forma Therapeutics Holdings Inc (NASDAQ: FMTX) shares are up 50% after announcing a definitive agreement with Novo Nordisk.

Forma Therapeutics shares jump 50%; here is why

FORMA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX

NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Forma Therapeutics Holdings, Inc. ("Forma Therapeutics" or the "Company") (NASDAQ: FMTX), in connection with the proposed acquisition of the Company by Novo Nordisk A/S (NYSE: NVO) via tender offer.

SHAREHOLDER ALERT: Weiss Law Investigates Forma Therapeutics Holdings, Inc.

Wilmington, Delaware--(Newsfile Corp. - September 1, 2022) - Rigrodsky Law, P.A. is investigating Forma Therapeutics Holdings, Inc. ("Forma") (NasdaqGM: FMTX) regarding possible breaches of fiduciary duties and other violations of law related to Forma's agreement to be acquired by Novo Nordisk A/S. Under the terms of the agreement, Forma's shareholders will receive $20.00 per share.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-forma-therapeutics-holdings-inc.To contact Seth D. Rigrodsky or Gina M.

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Forma Therapeutics Holdings, Inc. Buyout

The rare blood disorder specialist is the latest biotech buyout target.

Why Forma Therapeutics Holdings Stock Is On Fire Today

Novo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying. The post Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout appeared first on Investor's Business Daily.

Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout

MILWAUKEE , Sept. 1, 2022 /PRNewswire/ -- Ademi LLP is investigating Forma Therapeutics (NASDAQ: FMTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Novo Nordisk.

Shareholder Alert: Ademi LLP investigates whether Forma Therapeutics, Holdings Inc. has obtained a Fair Price in its transaction with Novo Nordisk

It's a newsworthy morning as Novo Nordisk (NYSE: NVO ) just announced that it will acquire Forma Therapeutics (NASDAQ: FMTX ). This is a $1.1 billion deal that will allow Novo Nordisk to expand its portfolio of blood disorder treatments.

Forma Therapeutics (FMTX) Stock Soars on Novo Nordisk Acquisition News

Novo Nordisk (NYSE: NVO) is buying Forma Therapeutics, Holdings Inc (Nasdaq: FMTX) for $1.1 billion. This is why.

Why Novo Nordisk (NVO) Is Buying Forma Therapeutics (FMTX) For $1.1 Billion

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Forma Therapeutics, Holdings Inc. (NASDAQ: FMTX) to Novo Nordisk for $20.00 per share in cash is fair to Forma shareholders. Halper Sadeh encourages Forma shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Forma a

FMTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Forma Therapeutics, Holdings Inc. Is Fair to Shareholders

Danish drugmaker Novo Nordisk will acquire Forma Therapeutics in a deal valued at $1.1 billion to expand its rare blood disorders portfolio, the companies said on Thursday.

Novo Nordisk to acquire Forma Therapeutics in $1.1. billion deal

Forma Therapeutics Holdings Inc. FMTX, +1.67% announced Thursday and agreement to be acquired by Denmark-based Novo Nordisk NVO, +0.06% NOVO.B, -0.59% in a deal with an equity value of $1.1 billion. Forma shares are halted for news until 8:30 a.m.

Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billion

Bagsværd, Denmark and Watertown, M ass, US , 01 September 2022 – Novo Nordisk and Forma Therapeutics, Holdings Inc. (Nasdaq: FMTX) today announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for USD 20 per share in cash, which represents a total equity value of USD 1.1bn. Forma Therapeutics is a clinical-stage biopharmaceutical company focused on transforming the lives of patients with sickle cell disease (SCD) and rare blood disorders.

Novo Nordisk to acquire Forma Therapeutics and expand presence in sickle cell disease and rare blood disorders

72% technical buy signal. 15 new highs and up 59.18% in the last month.

Forma Therapeutics: Rare Disease Play

Forma Therapeutics Holdings Inc. (NASDAQ:FMTX ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Adam Bero - Investor Relations Frank Lee - President and Chief Executive Officer Agustin Melian - Executive Vice President, Research and Development Cameron Trenor - Executive Director, Clinical Development Dave Cook - Chief Scientific Officer Todd Shegog - Chief Financial Officer Conference Call Participants Mark Breidenbach - Oppenheimer Maury Raycroft - Jefferies Andrew Berens - SVB Prakhar Agrawal - Cantor Operator Good morning, my name is Josh and I will be your conference operator today. At this time, I would like to welcome everyone to the Forma Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call.

Forma Therapeutics Holdings Inc. (FMTX) CEO Frank Lee on Q2 2022 Results - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Forma Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Rigel Pharmaceuticals

Registrational Phase 2 data demonstrate olutasidenib's potential as a market-leading, oral, mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor for the treatment of relapsed or refractory acute myeloid leukemia FDA has accepted Forma's NDA for olutasidenib, with a PDUFA target action date of February 15, 2023 Forma to receive an upfront payment of $2.0 million and is eligible to receive an additional $17.5 million upon the achievement of certain near-term regulatory, approval, and first commercial sale milestones, as well as potential future development and commercial milestone payments of $215.5 million and tiered royalties in the low-teens to mid-thirties If approved, olutasidenib would be Rigel's second commercial product in hematology-oncology and highly synergistic with Rigel's existing commercial and medical affairs infrastructure Rigel to host conference call today to discuss transaction details at 4:30 p.m. Eastern Time and will be joined by Key Opinion Leader and olutasidenib Phase 2 trial investigator, Jorge E.

Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022

Forma Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 5, 2022

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

News for Forma Therapeutics Holdings Stock (FMTX)